Weekly Digest – July 2024 Weekly Digest – July 2024 26 July 2024: BioAtla’s Ozuriftamab Vedotin Receives FDA Fast Track Designation for Recurrent or Metastatic Head and Neck Cancer BioAtla announced that the U.S. FDA granted Fast Track Designation (FTD) […]
Contact:
info@ciscientists.com
+1-908-212-7484
Optimal Dose
For a subscription, please provide your email id